Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
66.60 -1.43 (-2.10%) 19:41 ET [NYSE]
66.60 x 10 66.65 x 908
Realtime by (Cboe BZX)
66.60 x 10 66.65 x 908
Realtime 66.65 -1.59 (-2.33%) 19:28 ET
Profile for Wed, Apr 2nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.

Company Info

Novo Nordisk A/S ADR Novo Alle 1 Bagsvaerd G7 2880 DNK

www.novonordisk.com Employees: 77,349 P: 45-4444-8888

Sector:

Medical

Description:

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.

Key Statistics

Overview:

Market Capitalization, $K 305,286,816
Enterprise Value, $K 317,920,960
Shares Outstanding, K 4,487,532
Annual Sales, $ 42,108 M
Annual Net Income, $ 14,643 M
Last Quarter Sales, $ 12,261 M
Last Quarter Net Income, $ 4,027 M
EBIT, $ 18,609 M
EBITDA, $ 21,380 M
60-Month Beta 0.61
% of Insider Shareholders 0.07%
% of Institutional Shareholders 11.54%
Float, K 4,484,391
% Float 99.93%
Short Volume Ratio 0.27

Growth:

1-Year Return -46.04%
3-Year Return 12.86%
5-Year Return 126.77%
5-Year Revenue Growth 130.21%
5-Year Earnings Growth 166.67%
5-Year Dividend Growth 134.09%

Per-Share Information:

Most Recent Earnings 0.91 on 02/05/25
Next Earnings Date 05/01/25
Earnings Per Share ttm 3.29
EPS Growth vs. Prev Qtr 1.11%
EPS Growth vs. Prev Year 28.17%
Annual Dividend Rate, $ 1.15
Annual Dividend Yield 1.69%
Most Recent Dividend 0.787 on 03/31/25
Next Ex-Dividends Date 03/31/25
Dividend Payable Date 04/08/25
Dividend Payout Ratio 31.42%
Most Recent Split 2-1 on 09/20/23

NVO Ratios

Ratio
Price/Earnings ttm 21.11
Price/Earnings forward 18.00
Price/Earnings to Growth 1.10
Return-on-Equity % 84.68%
Return-on-Assets % 26.29%
Profit Margin % 34.78%
Debt/Equity 0.72
Price/Sales 7.40
Price/Cash Flow 17.89
Price/Book 14.98
Book Value/Share 4.64
Interest Coverage 18.31

NVO Dividends

Date Value
03/31/25 $0.7870
08/16/24 $0.3620
03/22/24 $0.6630
08/18/23 $0.3120
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades